Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.


Clinical trials of oncolytic virotherapy have shown low toxicity and encouraging signs of efficacy. However, it remains critically important to develop methods for systemic viral delivery if such therapies are to be clinically implemented to treat established tumors. In this respect, much effort is being focused on combining oncolytic viruses with standard… (More)
DOI: 10.1172/JCI41431

7 Figures and Tables


  • Blog articles referencing this paper

  • Presentations referencing similar topics